Slapped Cheek Syndrome (Fifth Disease/Parvovirus B19)

1. Clinical Overview

Summary

Slapped Cheek Syndrome (Erythema Infectiosum), historically termed "Fifth Disease" as the fifth described childhood exanthem, is a common viral infection caused by Human Parvovirus B19 (B19V). This small, non-enveloped, single-stranded DNA virus predominantly affects school-aged children (5-15 years), presenting with a characteristic biphasic illness: a mild prodromal phase followed by a distinctive facial rash resembling "slapped cheeks" and a subsequent lacy, reticular body rash. [1,2]

While typically self-limiting and benign in immunocompetent children, Parvovirus B19 has unique tropism for erythroid progenitor cells via the P antigen (globoside) receptor, making it potentially devastating in three specific populations: (1) patients with chronic haemolytic anaemias (sickle cell disease, hereditary spherocytosis, thalassaemia) who may develop transient aplastic crises; (2) immunocompromised individuals who may develop chronic pure red cell aplasia; and (3) pregnant women, particularly in the first 20 weeks, where vertical transmission can cause fetal anaemia, hydrops fetalis, and intrauterine death. [3,4,5]

Critical paradox: By the time the characteristic rash appears, the patient is no longer infectious. Infectivity occurs during the prodromal phase when symptoms are non-specific (fever, malaise, coryza), making prevention of transmission challenging. Management is predominantly supportive for uncomplicated cases, with specific interventions reserved for high-risk groups: blood transfusion for aplastic crises, intravenous immunoglobulin (IVIG) for chronic infection in immunocompromised patients, and intrauterine transfusion for fetal hydrops. [6,7]

Key Facts

• Causative Pathogen: Human Parvovirus B19 - smallest DNA virus to infect humans (5.6kb genome)
• Epidemiology: Worldwide distribution with seasonal peaks (late winter/spring); endemic with epidemic cycles every 3-4 years
• Transmission: Respiratory droplets (primary), vertical transmission (maternal-fetal), parenteral (blood products, rare with current screening)
• Incubation Period: 4-14 days (range up to 21 days)
• Infectivity Window: 7-10 days before rash onset (during prodrome); NON-INFECTIOUS once rash appears
• Secondary Attack Rate: 50% in household contacts; up to 20-30% in school settings during outbreaks [8]

The Paradox of Infectivity

Exam Detail: Key Examination Concept: Understanding the temporal relationship between infectivity and clinical manifestations is critical for exam questions:

• Viraemic Phase (Days 5-10 post-exposure): High viral load, constitutional symptoms, respiratory spread. Patient is highly infectious but diagnosis not yet apparent.
• Immune Complex Phase (Days 14-21): Rash and arthropathy develop due to immune complex deposition. Viral load declining, patient not infectious.
• Clinical Implication: School exclusion policies are ineffective since transmission occurs before diagnosis. Public Health England (PHE/UKHSA) guidance: no exclusion necessary once rash appears. [9]

Clinical Pearls

School Exclusion Policy: There is NO indication to exclude children with the characteristic rash from school or childcare. They were infectious during the prodromal phase (fever, coryza) 1-2 weeks earlier when symptoms were indistinguishable from common colds. Once the "slapped cheeks" appear, viraemia has cleared and infectivity has ceased. [9]

The "Reticulocyte Count Test": In children with sickle cell disease presenting with severe anaemia, the reticulocyte count differentiates aplastic crisis from other complications:

• Low/absent reticulocytes (less than 0.2%): Aplastic crisis (Parvovirus B19) - bone marrow arrest
• High reticulocytes (> 5%): Splenic sequestration or hyperhaemolysis - intact marrow response
• Mechanism: B19V destroys erythroid progenitors → reticulocytopenia → profound anaemia in high-turnover states [10]

"Gloves and Socks" Syndrome: Papular-Purpuric Gloves and Socks Syndrome (PPGSS) is an atypical presentation characterized by painful erythema, petechiae, and oedema of hands and feet with sharp demarcation at wrists/ankles. Unlike classic slapped cheek, patients with PPGSS may still be infectious during rash. Also associated with fever, oral lesions. [11]

Adult Arthropathy: While children rarely develop joint symptoms, up to 60% of adult women with acute B19V infection develop acute symmetrical polyarthropathy affecting small joints (hands, wrists, knees, ankles). Mimics rheumatoid arthritis but is seronegative and self-limiting (resolves in weeks-months, though can persist up to 2 years in some cases). Adult men and children have less than 10% arthropathy risk. [12,13]

P Antigen-Negative Immunity: Rare individuals lacking the P antigen (globoside) receptor are naturally immune to B19V infection. This occurs in approximately 1 in 200,000 individuals. The P antigen is also the blood group antigen, and P-null individuals are resistant to infection. [14]

---

2. Epidemiology

Global Distribution

Parvovirus B19 infection occurs worldwide with no significant geographic, racial, or sex predilection. Seroprevalence studies demonstrate progressive acquisition of immunity with age, reflecting cumulative exposure throughout life. [15]

Key Point: 40-50% of women of childbearing age are seronegative (non-immune), placing them at risk for primary infection during pregnancy. [16]

Seasonal Patterns and Epidemic Cycles

Exam Detail: Seasonality:

• Temperate climates: Peak incidence in late winter and spring (February-May in Northern Hemisphere)
• Tropical regions: Less pronounced seasonality but year-round transmission

Epidemic Cycles:

• Endemic circulation with epidemic outbreaks every 3-4 years
• School-based outbreaks common due to high susceptibility in children
• Outbreaks may involve 10-60% of susceptible students
• Occupational risk: Schoolteachers, daycare workers, and healthcare personnel have increased exposure [8,15]

Transmission Dynamics

Primary Route: Respiratory Droplets

• Mechanism: Coughing, sneezing, close contact during viraemic phase
• Viral Shedding: Nasal and oropharyngeal secretions contain high viral load (10^10-10^11 genome copies/mL) during prodrome
• Secondary Attack Rates:
  • "Household contacts: 50%"
  • "Classroom contacts: 20-30%"
  • "Healthcare workers: Estimated 35% in outbreak settings [17]"

Vertical Transmission (Maternal-Fetal)

• Mechanism: Transplacental passage during maternal viraemia
• Transmission Rate: 30-50% of maternal infections result in fetal infection
• Timing Matters:
  • "First trimester (less than 13 weeks): 10-15% fetal loss rate"
  • "Second trimester (13-20 weeks): 2-6% risk of hydrops fetalis"
  • "Third trimester (> 20 weeks): less than 1% risk of significant fetal complications [18,19]"

Parenteral Transmission

• Blood Products: Historically significant but now rare due to:
  • Nucleic acid testing (NAT) of donated blood
  • Viral inactivation procedures for plasma products
• Risk: Clotting factor concentrates (haemophilia patients) - now screened
• Organ Transplantation: Rare case reports of transmission via solid organ transplant [20]

Age Distribution

Paediatric Cases (Classic Presentation)

• Peak Age: 5-15 years (school-aged children)
• Presentation: Erythema infectiosum (slapped cheek rash) in 75-80%
• Arthropathy: Rare (less than 10%)
• Reason: First exposure typically occurs in childhood via school outbreaks

Adult Cases

• Presentation:
  • Rash present in only 15-20% of adults (facial rash particularly rare)
  • Arthropathy is predominant manifestation (50-60% of cases, especially women)
• Differential Diagnosis: Often mistaken for early rheumatoid arthritis, systemic lupus erythematosus, or viral polyarthritis

High-Risk Populations

---

3. Aetiology and Pathophysiology

Viral Structure and Classification

Human Parvovirus B19 (B19V) is a member of the Parvoviridae family, genus Erythroparvovirus.

• Structure:
  • Non-enveloped icosahedral capsid (22-24 nm diameter)
  • Single-stranded DNA genome (5.6 kilobases)
  • Smallest DNA virus capable of infecting humans
• Stability: Highly resistant to:
  • Heat (survives 56°C for > 60 minutes)
  • pH extremes (pH 3-9)
  • Lipid solvents (non-enveloped)
  • Desiccation (can survive on surfaces)
• Genotypes: Three genotypes (1, 2, 3) with genotype 1 most common in clinical infections [1,21]

Molecular Pathophysiology

Viral Entry and Tropism

Exam Detail: Step 1: Receptor Binding

• Primary Receptor: P antigen (Globoside/Gb4Cer) - glycosphingolipid on cell membrane
  • "Highly expressed on: Erythroid progenitor cells (CFU-E, proerythroblasts), megakaryocytes, endothelial cells, fetal myocardium"
  • "Low/absent expression on: Most somatic cells, mature erythrocytes"
• Co-receptors: α5β1 integrin, Ku80 autoantigen (facilitate viral entry)

Clinical Correlation:

• P antigen distribution explains tissue tropism and clinical manifestations
• Erythroid progenitors → aplastic anaemia
• Fetal myocardium → myocarditis, hydrops
• Endothelium → vasculitis (gloves and socks syndrome)

Step 2: Viral Replication

• Requires actively dividing cells (parvovirus lacks genes for DNA synthesis)
• Replicates in S-phase of cell cycle
• Erythroid progenitors in bone marrow are ideal targets (rapid turnover, high P antigen expression)

Step 3: Cell Lysis

• Direct cytopathic effect on infected cells
• Apoptosis of erythroid progenitors
• Result: Arrest of erythropoiesis for 7-10 days [22,23]

Impact on Erythropoiesis: The "Red Cell Lifespan Calculation"

Understanding why B19V causes severe anaemia in some patients but not others requires knowledge of red blood cell kinetics:

Normal Host:

• RBC lifespan: 120 days
• Daily RBC turnover: ~0.8% (1/120)
• Effect of 7-10 day arrest: Minimal Hb drop (5-10 g/L) - often asymptomatic
• Reticulocytes fall transiently but Hb remains stable due to large circulating RBC reserve

Chronic Haemolytic Anaemia (e.g., Sickle Cell Disease):

• RBC lifespan: 10-20 days (severe haemolysis)
• Daily RBC turnover: 5-10%
• Baseline reticulocyte count: 10-20% (compensatory)
• Bone marrow operates at maximal capacity to maintain steady-state Hb
• Effect of 7-10 day arrest:
  • Reticulocytes drop to near-zero
  • No new RBCs produced but ongoing destruction continues
  • Hb falls precipitously (can drop 30-50 g/L in days)
  • Transient Aplastic Crisis - life-threatening anaemia [10,24]

Fetal Erythropoiesis:

• RBC lifespan: 45-70 days (shorter than adult)
• Rapidly expanding blood volume (growth)
• High metabolic demands
• Effect of B19V:
  • Severe fetal anaemia develops
  • High-output cardiac failure
  • Ascites, pleural effusions, skin oedema
  • Non-immune hydrops fetalis [25]

Immunopathogenesis

The clinical manifestations of B19V infection occur in two distinct phases, each mediated by different mechanisms:

Phase 1: Viraemia (Days 5-10 Post-Infection)

• Mechanism: Direct viral cytopathic effects
• Viral Load: Peak at 10^11-10^13 genome copies/mL
• Clinical Features:
  • Flu-like prodrome (fever, malaise, headache, myalgia)
  • Mild respiratory symptoms (coryza, sore throat)
  • Bone marrow suppression (reticulocytopenia, leucopenia, thrombocytopenia)
• Infectivity: HIGHLY INFECTIOUS - respiratory droplet spread
• Laboratory: High serum B19V DNA by PCR; IgM not yet positive [26]

Phase 2: Immune Complex Disease (Days 14-21 Post-Infection)

• Mechanism: IgM and IgG antibody production → immune complex formation and deposition
• Viral Load: Decreasing/cleared from blood
• Clinical Features:
  • "Rash: Erythema infectiosum (slapped cheek, lacy reticular rash)"
    • Mediated by immune complex deposition in dermal vessels
    • Can recur with heat, sunlight, stress (recirculation of immune complexes)
  • "Arthropathy: Symmetrical polyarthritis/arthralgia"
    • Immune complex deposition in synovium
    • More common in adults (especially women) - possibly oestrogen-related
  • "Pruritis: Can be prominent in some patients"
• Infectivity: NON-INFECTIOUS (virus cleared, antibodies present)
• Laboratory: IgM positive (acute/recent), IgG rising (developing immunity) [12,13,27]

Variant Presentations and Their Mechanisms

Papular-Purpuric Gloves and Socks Syndrome (PPGSS)

• Presentation: Painful oedema and erythema of hands/feet with sharp cut-off at wrists/ankles; petechiae and purpura; oral lesions
• Mechanism:
  • Vasculitis due to immune complex deposition in dermal capillaries
  • Endothelial cell infection (P antigen expressed on endothelium)
• Key Difference: Patients may still be viraemic during rash (unlike classic erythema infectiosum)
• Differential: Also associated with EBV, CMV, HHV-6, Coxsackie B [11]

Hydrops Fetalis

• Mechanism:
  1. Fetal erythroid progenitor infection → severe anaemia
  2. Fetal myocarditis (P antigen on fetal cardiomyocytes) → cardiac dysfunction
  3. Hepatic erythropoiesis disruption → decreased albumin synthesis
  4. Combined Effect: High-output cardiac failure + hypoalbuminaemia → generalized oedema (skin, pleural, peritoneal, pericardial)
• Ultrasound Findings: Skin thickening > 5mm, ascites, pleural effusions, pericardial effusion, placentomegaly
• MCA Doppler: Elevated peak systolic velocity (> 1.5 MoM) indicates fetal anaemia (reduced blood viscosity → increased flow velocity) [25,28]

Chronic Pure Red Cell Aplasia (PRCA)

• Patient Group: Immunocompromised (HIV, transplant, chemotherapy, congenital immunodeficiency)
• Mechanism:
  • Inability to produce neutralizing antibodies
  • Persistent viral replication in bone marrow
  • Ongoing erythroid progenitor destruction
• Presentation: Chronic transfusion-dependent anaemia (weeks-months)
• Diagnosis: Persistently positive B19V DNA by PCR; absent or low IgG
• Treatment: IVIG (provides passive antibodies to clear virus) [29,30]

---

4. Clinical Presentation

Classic Paediatric Presentation: Erythema Infectiosum

Three-Stage Rash Evolution

Stage 1: "Slapped Cheek" Appearance (Days 14-16 post-infection)

• Description: Sudden onset of bright red erythema over both cheeks (malar regions)
• Key Features:
  • Spares nasolabial folds → characteristic pattern
  • Spares periorbital areas ("circumoral pallor")
  • Often warm to touch but not painful
  • May have mild facial oedema
  • Can be unilateral initially
• Duration: 1-4 days
• Associated Symptoms: Usually well; fever has typically resolved by this stage

Stage 2: Reticular Body Rash (Days 17-20)

• Onset: 1-4 days after facial rash
• Distribution:
  • Proximal limbs first (upper arms, thighs)
  • Spreads to trunk, extensor surfaces of limbs
  • Spares palms and soles (cf. PPGSS)
• Appearance:
  • Initially maculopapular erythema
  • Evolves to lacy/reticular (net-like) pattern as centres clear
  • "Lace-like" or "net curtain" appearance is pathognomonic
• Duration: 1-3 weeks (variable)

Stage 3: Recurrent/Fluctuant Rash (Weeks-Months)

• Trigger Factors:
  • Heat (hot baths, exercise)
  • Sunlight/UV exposure
  • Emotional stress
  • Cold exposure
• Mechanism: Recirculation or visualization of immune complexes in dermal capillaries
• Reassurance Point: Does NOT indicate reinfection or renewed infectivity
• Duration: Can recur intermittently for up to 3 months [2,31]

Prodromal Phase

Occurs 5-10 days before rash (during peak viraemia):

• Low-grade fever (37.5-38.5°C)
• Malaise, fatigue
• Headache
• Myalgia
• Coryza (runny nose)
• Mild sore throat
• Often mistaken for common cold
• Duration: 2-3 days

Clinical Pearl: Patients are most infectious during this phase, but diagnosis is not suspected. Retrospective recognition only occurs when rash appears 1-2 weeks later.

Adult Presentation

Adults with B19V infection present differently than children:

Arthropathy (Dominant Feature)

• Incidence:
  • "Adult women: 60%"
  • "Adult men: 30%"
  • "Children: less than 10%"
• Onset: Coincides with rash (immune complex phase) or may occur without rash
• Pattern: Symmetrical polyarthropathy
  • "Small joints: MCP, PIP, wrists, ankles, knees"
  • Bilateral and symmetrical
  • Can mimic rheumatoid arthritis
• Characteristics:
  • Morning stiffness (30-60 minutes)
  • Joint swelling and tenderness
  • Seronegative (RF negative, anti-CCP negative)
  • "X-rays: No erosive changes"
• Duration:
  • "Most cases: 2-4 weeks"
  • 20% of cases: Symptoms persist > 2 months
  • "Rare cases: Up to 2 years (but eventually resolves)"
• Treatment: NSAIDs, analgesia; self-limiting [12,13,32]

Rash in Adults

• Incidence: Only 15-20% (vs. 75-80% in children)
• Facial rash: Rare
• Body rash: Non-specific maculopapular or reticular pattern
• Diagnosis: Often relies on serology rather than clinical recognition

High-Risk Presentations

Transient Aplastic Crisis (TAC)

Patient Profile:

• Known chronic haemolytic anaemia:
  • Sickle cell disease (most common)
  • Hereditary spherocytosis
  • Thalassaemia
  • Pyruvate kinase deficiency
  • Autoimmune haemolytic anaemia
  • Diamond-Blackfan anaemia

Presentation:

• Sudden onset severe anaemia (Hb drop of 30-50 g/L over 1-3 days)
• Profound pallor (pale lips, tongue, conjunctivae, palmar creases)
• Extreme lethargy, weakness
• Breathlessness, tachycardia, tachypnoea
• Congestive heart failure signs (in severe cases)
• Absence of jaundice (key differentiator from haemolytic crisis)
• Often NO RASH (anaemia develops during viraemic phase before rash appears)

Examination Findings:

• Severe pallor
• Tachycardia, tachypnoea
• Flow murmur (high-output state)
• Signs of underlying condition (splenomegaly in spherocytosis/sickle cell)

Laboratory Features: [10,24,33]

• Severe anaemia (Hb 40-70 g/L, often less than 60 g/L)
• Reticulocytopenia (less than 0.2%, often near-zero) - DIAGNOSTIC KEY
• Leucopenia, thrombocytopenia (bone marrow suppression)
• Normal/slightly elevated bilirubin (reduced from baseline in haemolytic conditions)
• B19V IgM positive (or PCR positive if early)

Exam Detail: OSCE/Viva Question: "A 7-year-old with sickle cell disease presents with severe anaemia (Hb 58 g/L). How do you differentiate aplastic crisis from other causes?"

Model Answer: "I would check the reticulocyte count immediately:

1. Reticulocytopenia (less than 0.2%) suggests Aplastic Crisis (Parvovirus B19):

   • Bone marrow arrest
   • Check B19V IgM or PCR
   • Management: Blood transfusion, supportive care
   • Marrow recovers in 7-10 days

2. High reticulocytes (> 5%) indicates ongoing haemolysis with intact marrow response:

   • Splenic Sequestration: Sudden splenomegaly, circulatory compromise
   • Hyperhaemolytic Crisis: Jaundice, increased LDH, high bilirubin

3. Additional differentiators:

   • Aplastic crisis: Pallor WITHOUT jaundice (reduced RBC destruction during aplasia)
   • Sequestration: Rapidly enlarging spleen, hypovolaemia
   • Hyperhaemolysis: Jaundice, dark urine, trigger factor (infection, drugs)

The reticulocyte count is the single most useful discriminating test."

B19V in Pregnancy

Maternal Symptoms:

• Often asymptomatic (30-50% of infections)
• Non-specific viral illness if symptomatic
• Rash (20%), arthralgia (60%)
• Rarely severe in immunocompetent mothers

Fetal Risks: [18,19,25,28]

Key Points:

• Peak risk period: 13-20 weeks gestation
• No teratogenic effects (unlike rubella, CMV, Zika)
• Hydrops typically develops 2-6 weeks after maternal infection
• Spontaneous resolution of hydrops occurs in ~30% of cases
• Intrauterine transfusion improves survival to > 80% in hydrops cases

Monitoring:

• Weekly ultrasound for 12 weeks post-maternal infection
• Middle Cerebral Artery (MCA) Doppler: Elevated peak systolic velocity (PSV > 1.5 MoM) indicates fetal anaemia
• Referral to Fetal Medicine for suspected hydrops

Immunocompromised Patients: Chronic Pure Red Cell Aplasia

Patient Groups:

• HIV/AIDS (especially low CD4)
• Solid organ or bone marrow transplant recipients
• Chemotherapy patients
• Congenital immunodeficiencies
• Chronic corticosteroid use

Presentation:

• Persistent anaemia (weeks to months)
• Transfusion-dependent
• No rash (lack of immune response)
• Reticulocytopenia
• Diagnosis: Persistently positive B19V PCR, low/absent IgG

Treatment: IVIG (0.4 g/kg/day for 5-10 days) - provides passive antibodies to clear virus [29,30]

Atypical and Rare Presentations

Papular-Purpuric Gloves and Socks Syndrome (PPGSS)

• Age: Typically young adults
• Presentation:
  • Painful erythema and oedema of hands and feet
  • Sharp demarcation at wrists/ankles (glove/sock distribution)
  • Petechiae and purpura on affected areas
  • Oral lesions (petechiae on palate, tongue)
  • Fever
• Duration: 1-2 weeks
• Key Point: May still be infectious (unlike classic erythema infectiosum) [11]

Neurological Manifestations (Rare)

• Encephalitis, meningitis
• Peripheral neuropathy
• Brachial plexopathy
• Mechanism: Direct viral neurotropism vs. immune-mediated

Cardiac Manifestations (Rare)

• Myocarditis (can occur in children and adults, not just fetuses)
• Heart failure, arrhythmias
• Usually self-limiting but can be severe

Haematological (Beyond Aplastic Crisis)

• Thrombocytopenic purpura
• Neutropenia (transient during viraemia)
• Haemophagocytic lymphohistiocytosis (HLH) - very rare

Hepatitis

• Transient elevation of transaminases
• Rare fulminant hepatic failure cases reported

---

5. Differential Diagnosis

Paediatric Rash Differential

Exam Detail: High-Yield for MRCPCH: Differentiate the childhood exanthems (all can present with fever and rash)

Adult Arthropathy Differential

When an adult (especially a woman) presents with acute symmetrical polyarthritis, consider:

Examination Key: In suspected parvovirus arthropathy:

• Check for rash (may be subtle or absent in adults)
• Ask about contact with children with rash (school, family)
• Check pregnancy status (women of childbearing age)
• Send B19V IgM/IgG serology
• RF and anti-CCP will be negative (unlike RA)

Pregnancy Exposure Differential

When evaluating rash in pregnancy or exposure to childhood illness:

Key Point: Parvovirus B19 is NOT teratogenic - it does not cause structural malformations. The risk is haematological (fetal anaemia and secondary hydrops), not developmental.

---

6. Investigations

Clinical Diagnosis (Uncomplicated Cases)

In healthy children with typical presentation:

• Diagnosis is CLINICAL
• No investigations required
• Characteristic slapped cheek + lacy rash is sufficient for diagnosis
• Inform parents about recurrent rash with heat/sun
• Reassure regarding school attendance (not infectious once rash present)

Indications for Laboratory Testing

Serology and/or PCR should be performed in:

1. Pregnant woman exposed to B19V (most important indication)
2. Patient with chronic haemolytic anaemia presenting with severe anaemia
3. Immunocompromised patient with unexplained persistent anaemia
4. Adult with acute symmetrical polyarthropathy (unknown cause)
5. Investigation of non-immune hydrops fetalis
6. Screening of blood/organ donors (in outbreak settings)
7. Healthcare/school outbreak investigation (public health indication)

Serological Testing

Exam Detail: B19V IgM and IgG Interpretation:

Timing of Antibody Response:

• IgM appears: 10-14 days post-infection (around time rash appears)
• IgM peaks: 30 days
• IgM persists: 2-3 months (occasionally up to 6 months)
• IgG appears: 14-21 days post-infection
• IgG persists: Lifelong immunity

Important Caveat:

• Immunocompromised patients may NOT produce IgM or IgG despite active infection
• If clinical suspicion in immunocompromised: proceed directly to PCR testing

Molecular Testing (PCR)

Indications for B19V DNA PCR:

1. Immunocompromised patients (may not mount antibody response)
2. Suspected chronic infection/PRCA (persistent viraemia)
3. Intrauterine infection: Amniotic fluid PCR (if amniocentesis performed)
4. Very early infection (before IgM becomes positive)
5. Blood/organ donor screening

Sample Types:

• Serum/plasma (most common)
• Amniotic fluid (fetal infection)
• Bone marrow (in aplastic crisis or PRCA investigation)

Interpretation:

• High viral load (> 10^6 copies/mL): Active replication, highly suggestive of current infection
• Low viral load: May represent persistent DNA (not necessarily active infection)
• Negative: Does not exclude recent infection if already cleared (rely on serology)

Haematological Investigations

In Suspected Aplastic Crisis

Full Blood Count (FBC):

• Haemoglobin: Severe anaemia (40-70 g/L, often less than 60 g/L)
  • Much lower than patient's baseline Hb
  • "In sickle cell disease: Baseline often 70-90 g/L, TAC drops to 40-60 g/L"
• Leucocytes: Leucopenia (WCC 2-4 × 10^9/L) during viraemic phase
  • Neutropenia
• Platelets: Thrombocytopenia (100-150 × 10^9/L) - usually mild

Reticulocyte Count: [10,33]

• Diagnostic Key: Reticulocytopenia (less than 0.2%, often less than 0.1% or absent)
• Significance: Differentiates aplastic crisis from other causes of anaemia in haemolytic conditions
  • "Haemolysis with intact marrow: High reticulocytes (> 5%, often 10-20%)"
  • "Aplastic crisis: Low/absent reticulocytes (marrow arrest)"

Blood Film:

• Absence of polychromasia (reflects reticulocytopenia)
• Features of underlying condition (sickle cells, spherocytes, etc.)
• No new RBC production evident

Other Tests:

• Bilirubin: Normal or lower than baseline (reduced haemolysis during aplasia)
• LDH: May be slightly elevated but less than during haemolytic episodes
• Haptoglobin: May normalize (reduced haemolysis)

Bone Marrow (Rarely Needed):

• Giant pronormoblasts with eosinophilic nuclear inclusions (pathognomonic for B19V)
• Erythroid aplasia (absent late-stage erythroid precursors)
• Reserved for unclear cases or research

In Immunocompromised (Suspected PRCA)

• Persistent anaemia (weeks-months)
• Reticulocytopenia
• Normal WCC and platelets (unless other factors)
• B19V PCR persistently positive
• IgM/IgG may be low or absent

Pregnancy-Specific Investigations

Maternal Assessment

Initial Evaluation (Pregnant Woman Exposed to B19V):

1. Confirm exposure: Household contact? Occupational (teacher)? Outbreak?
2. Gestational age: Risk stratification
3. Maternal B19V IgM/IgG serology:
   • If IgG positive: Immune, reassure
   • If both negative: Susceptible, repeat in 4 weeks
   • If IgM positive: Acute infection, refer to Fetal Medicine

Fetal Assessment (If Maternal Infection Confirmed)

Ultrasound Surveillance: [18,19,28]

• Frequency: Weekly for 12 weeks post-maternal infection
  • Hydrops typically develops 2-6 weeks post-maternal infection
  • Can rarely occur up to 12 weeks later
• What to Look For:
  • "Skin oedema: Subcutaneous fluid > 5mm"
  • "Ascites: Intra-abdominal fluid"
  • "Pleural effusions: Fluid around lungs"
  • "Pericardial effusion: Fluid around heart"
  • "Polyhydramnios: Increased amniotic fluid"
  • "Placentomegaly: Thickened placenta (> 4cm)"
  • "Cardiomegaly: Enlarged heart"
  • "Diagnosis of hydrops: Fluid in ≥2 body compartments"

Middle Cerebral Artery (MCA) Doppler:

• Purpose: Non-invasive assessment of fetal anaemia
• Mechanism:
  • Fetal anaemia → reduced blood viscosity → increased flow velocity
  • MCA is most sensitive vessel for this measurement
• Measurement: Peak Systolic Velocity (PSV)
• Interpretation: [34]
  • "PSV > 1.5 MoM (Multiples of Median for gestational age): Moderate-severe fetal anaemia"
  • "PSV > 1.55 MoM: Indication for intrauterine transfusion"
• Advantage: Avoids invasive procedures (cordocentesis) for anaemia assessment

Cordocentesis (Fetal Blood Sampling):

• Only if intervention planned (intrauterine transfusion)
• Direct measurement of fetal Hb
• B19V PCR on fetal blood
• Risk: 1-2% fetal loss

Amniocentesis:

• Not routinely indicated
• B19V PCR on amniotic fluid can confirm fetal infection but doesn't predict severity

Outbreak Investigation (Public Health)

In school or healthcare outbreaks:

• Serology on exposed pregnant staff/students (if non-immune or unknown)
• Pregnant women: Determine immunity status, counsel on risk
• Immunocompromised: Assess exposure, monitor FBC
• Case definitions for epidemiological tracking

---

7. Management

Management Algorithm

                    SUSPECTED PARVOVIRUS B19 INFECTION
                                   ↓
      ┌────────────────────────────┴────────────────────────────┐
      │                    RISK STRATIFICATION                   │
      │  • Pregnancy?                                            │
      │  • Chronic haemolytic anaemia (sickle cell, spherocytosis)?│
      │  • Immunocompromised?                                    │
      │  • Healthy child/adult?                                  │
      └────────────────────────────┬────────────────────────────┘
                                   ↓
    ┌──────────────┬───────────────┴───────────────┬────────────────┐
    │              │                               │                │
┌───▼────┐  ┌──────▼──────┐             ┌─────────▼─────────┐  ┌───▼────────┐
│PREGNANT│  │HAEMOLYTIC   │             │IMMUNOCOMPROMISED  │  │UNCOMPLICATED│
│ WOMAN  │  │ANAEMIA      │             │                   │  │(Healthy)    │
└───┬────┘  └──────┬──────┘             └─────────┬─────────┘  └───┬────────┘
    │              │                              │                │
    │         Severe anaemia?                     │                │
    │         Reticulocytes less than 0.2%?                │                │
    │              │                              │                │
    │          ┌───▼───┐                          │                │
    │          │Aplastic│                         │                │
    │          │Crisis  │                         │                │
    │          └───┬───┘                          │                │
    │              │                              │                │
    ▼              ▼                              ▼                ▼
┌────────────┐ ┌────────────┐            ┌─────────────┐  ┌──────────────┐
│• Serology  │ │• URGENT    │            │• FBC + Retics│  │• Reassurance │
│• If IgM+:  │ │• Admit     │            │• B19V PCR    │  │• Symptomatic │
│  FETAL MED │ │• Transfuse │            │• If confirmed:│  │• Paracetamol │
│• Weekly    │ │• Oxygen    │            │  IVIG therapy│  │• School OK   │
│  USS +     │ │• Monitor   │            │• Hb support  │  │• Hydration   │
│  MCA Doppler│ │• Isolation│            │              │  │              │
│• IUT if    │ │            │            │              │  │              │
│  hydrops   │ │            │            │              │  │              │
└────────────┘ └────────────┘            └─────────────┘  └──────────────┘

---

1. Uncomplicated Cases (Healthy Children and Adults)

Management Principles

The vast majority of B19V infections are self-limiting and require only supportive care.

Symptomatic Treatment:

• Antipyretics: Paracetamol 15 mg/kg every 4-6 hours (maximum 4 doses/24h) for fever/discomfort
  • Ibuprofen 10 mg/kg every 6-8 hours as alternative/additional
• Hydration: Encourage oral fluids
• Rest: As needed (usually minimal systemic upset once rash appears)
• Antipruritic:
  • Emollients for itching
  • Antihistamines (chlorphenamine, cetirizine) if pruritis significant

Education and Counselling: [6,9]

Exam Detail: Key Counselling Points (High-Yield for Communication Skills Stations):

1. Infectivity and School Exclusion:

   • "Your child was infectious last week when they had the cold symptoms (fever, runny nose)"
   • "Now that the rash has appeared, the infection is no longer contagious"
   • "There is no need to keep them off school if they feel well enough to attend"
   • "They can play with other children normally"

2. Rash Recurrence:

   • "The rash may fade and come back over the next few weeks"
   • "This happens with heat (hot baths, running around, sunshine), stress, or cold"
   • "This is completely normal and does NOT mean they are infectious again or have a new infection"
   • "It's just the immune system's reaction becoming visible again"

3. Duration:

   • "The rash usually clears completely within 1-3 weeks"
   • "Occasionally it can recur for up to 2-3 months with triggers"

4. When to Seek Medical Attention:

   • "If your child becomes unusually pale, very tired, or breathless" (anaemia - though rare in healthy children)
   • "If fever returns or new symptoms develop" (possible secondary infection)

5. Contact Tracing:

   • Ask about pregnant contacts (family members, teachers)
   • Ask about contacts with sickle cell disease or other blood conditions
   • If identified, advise them to seek medical advice for testing/counselling

Adult Arthropathy Management:

• NSAIDs: Ibuprofen 400 mg TDS or Naproxen 500 mg BD for symptomatic relief
• Analgesia: Paracetamol 1g QDS
• Reassurance: Self-limiting, no chronic arthritis, no erosive damage
• Timeframe: Usually resolves in 2-4 weeks, can persist several months but eventually resolves
• No role for DMARDs or corticosteroids

Follow-Up:

• Not required for uncomplicated cases
• Advise to return if symptoms worsen or new concerns

---

2. Pregnancy Exposure and Infection

UK Guidance: Royal College of Obstetricians and Gynaecologists (RCOG) Green-Top Guideline No. 4 [35]

Step 1: Confirm Significant Exposure

Significant Exposure Defined As:

• Household contact with confirmed or suspected case
• Occupational exposure (teacher, childcare worker, healthcare)
• Prolonged close contact (> 15 minutes) with infected individual

Timing: If exposure occurred during infectious period (prodromal phase, 7-10 days before rash in contact)

Step 2: Maternal Serological Testing

Urgent B19V IgM and IgG serology (within 1-2 days of presentation):

Result Interpretation and Action:

Most common scenario: IgG positive (50-60% of pregnant women are immune) → reassure and discharge.

Step 3: Fetal Medicine Management (If Maternal Infection Confirmed)

Surveillance Protocol: [18,28,35]

1. Weekly Ultrasound Scan for 12 weeks post-maternal infection:

   • Look for signs of hydrops fetalis (see Investigations section)
   • Most hydrops occurs 2-6 weeks post-infection, but can be delayed up to 12 weeks

2. Middle Cerebral Artery (MCA) Doppler:

   • Perform weekly alongside ultrasound
   • MCA-PSV > 1.5 MoM indicates moderate-severe fetal anaemia
   • Prompts consideration of intrauterine transfusion

3. If Hydrops Detected:

   • Cordocentesis: Measure fetal Hb, confirm B19V PCR
   • Intrauterine Transfusion (IUT): If severe fetal anaemia
     • Technique: Ultrasound-guided transfusion into umbilical vein
     • May require repeat transfusions (weekly) until fetal haematopoiesis recovers
     • Recovery typically occurs over 6-8 weeks
     • Survival: > 80% with IUT (vs. high mortality if untreated)

4. Spontaneous Resolution:

   • ~30% of hydrops cases resolve spontaneously without intervention
   • Close monitoring required to determine if IUT needed

Risk Counselling: [19]

• Overall fetal loss rate: 6-10% if maternal infection in pregnancy
• Risk stratified by gestational age:
  • less than 13 weeks: 10-15% loss
  • 13-20 weeks: 2-6% hydrops risk

  • 20 weeks: less than 1-2% significant complications

• No teratogenic risk: Unlike rubella/CMV, B19V does NOT cause structural malformations
• Long-term outcomes: Survivors of hydrops (treated or spontaneously resolved) have normal neurodevelopmental outcomes

Step 4: Delivery and Neonatal Care

• Timing of delivery: Usually not affected (unless severe hydrops requires early delivery)
• Mode of delivery: As per obstetric indications (B19V not an indication for caesarean section)
• Neonatal testing:
  • Cord blood B19V PCR
  • Neonatal Hb (anaemia may persist at birth)
• Breastfeeding: Safe (virus not transmitted via breast milk)

Occupational Health Considerations: [9,35]

• Pregnant healthcare workers/teachers:
  • Should be informed of B19V risk during outbreaks
  • If non-immune (IgG negative), consider redeployment to low-risk areas during outbreaks
  • No evidence that routine exclusion from work reduces risk (sporadic community exposure)
  • Individual risk assessment

---

3. Transient Aplastic Crisis (TAC)

High-Risk Patients: Sickle cell disease, hereditary spherocytosis, thalassaemia, pyruvate kinase deficiency, autoimmune haemolytic anaemia, Diamond-Blackfan anaemia [10,24,33]

Recognition and Diagnosis

Presentation:

• Sudden severe anaemia (Hb drop of 30-50 g/L)
• Extreme pallor, lethargy, breathlessness
• Tachycardia, tachypnoea
• Often no rash (anaemia develops during viraemic phase)

Key Investigation:

• Reticulocyte count less than 0.2% (diagnostic)
• Hb typically less than 60 g/L
• B19V IgM or PCR positive

Management

Immediate Actions (This is a medical emergency):

1. Urgent Admission:

   • Paediatric ward or HDU (if severely compromised)
   • Haematology involvement

2. Oxygen Therapy:

   • Target saturations > 94%
   • High-flow if respiratory distress

3. Blood Transfusion: [36]

   • Indication: Symptomatic anaemia, Hb less than 60 g/L, or cardiovascular compromise
   • Product: Packed red cells (leucodepleted, cross-matched)
   • Dose: 10-15 mL/kg over 3-4 hours
   • Target: Raise Hb to safe level (70-90 g/L) - avoid rapid over-transfusion (risk of hyperviscosity in sickle cell)
   • Monitoring: Cardiovascular status (risk of fluid overload)
   • Usually curative: Bone marrow recovers erythropoiesis within 7-10 days

4. Supportive Care:

   • IV fluids if dehydrated
   • Monitor vital signs
   • Cardiac monitoring if severe

5. Infection Control: [9]

   • Isolation: Side room if in hospital
   • Rationale: Protect other at-risk patients (other children with haemoglobinopathies)
   • Duration: Until IgM/IgG seroconversion documented or no longer viraemic
   • Respiratory precautions (droplet)

6. Contact Tracing:

   • Other siblings with haemoglobinopathy
   • Hospital contacts with sickle cell/spherocytosis

Recovery and Follow-Up

• Bone marrow recovery: 7-10 days (reticulocytes reappear, Hb rises)
• Discharge: Once Hb stabilized, clinically well
• Immunity: Lifelong after infection - aplastic crisis does not recur (IgG protection)
• Counselling: Educate family about immunity, no future risk
• Haematology follow-up: As per underlying condition

---

4. Chronic Pure Red Cell Aplasia (PRCA) in Immunocompromised

Patient Groups: HIV/AIDS, transplant recipients, chemotherapy, congenital immunodeficiency, chronic corticosteroids [29,30]

Recognition

• Persistent anaemia (weeks-months)
• Transfusion-dependent
• Reticulocytopenia
• No rash (lack of immune response)
• B19V PCR persistently positive (viral load remains high)
• IgM/IgG low or absent (cannot clear virus)

Management

1. Intravenous Immunoglobulin (IVIG): [37]

• Mechanism: Provides passive neutralizing antibodies to clear virus
• Dose:
  • "Standard: 0.4 g/kg/day for 5 days (total 2 g/kg)"
  • "Or: 1 g/kg/day for 2 days (alternative regimen)"
• Route: Slow IV infusion
• Response:
  • Reticulocyte count rises within 1-2 weeks
  • Hb increases over subsequent weeks
  • B19V PCR becomes negative
  • Transfusion independence achieved
• Success Rate: > 80% response to IVIG

2. Supportive Transfusions:

• Red cell transfusions as needed while awaiting IVIG response
• Maintain Hb > 70 g/L

3. Optimize Immune Function (if possible):

• HIV: Ensure optimal antiretroviral therapy (ART), aim for CD4 recovery
• Transplant: Reduce immunosuppression if feasible (balance rejection risk)
• Chemotherapy: Delay next cycle if possible

4. Monitor Response:

• Weekly FBC and reticulocytes
• Repeat B19V PCR at 2-4 weeks (should be negative or declining)

5. Relapse:

• 10-20% of patients relapse when IVIG wears off
• May require repeat courses or monthly maintenance IVIG

---

5. Public Health Measures

School and Childcare Exclusion Policy

UK Guidance (Public Health England/UKHSA): [9]

• Exclusion NOT recommended once rash appears (child not infectious)
• Notification: Inform school/childcare of diagnosis (for contact tracing)
• Pregnant staff: School should inform pregnant staff of case (allow them to seek medical advice)
• High-risk contacts: Notify families of children with sickle cell disease, immunocompromised

Healthcare Settings

• Healthcare worker with B19V: Not infectious once rash appears; can return to work if well
• Pregnant HCW: Should be offered serology if exposed; if non-immune, consider redeployment during outbreaks
• Patient isolation: Aplastic crisis patients should be isolated (may still be viraemic)

Outbreak Management

• Case definition: Clinical case (slapped cheek rash) or laboratory-confirmed
• Surveillance: Monitor number of cases in school/community
• Communication:
  • Letter to parents informing of outbreak
  • Advice for pregnant women and high-risk individuals to seek medical advice
• No school closure indicated (ineffective due to pre-rash transmission)

---

8. Complications

Haematological Complications

Pregnancy Complications

Important:

• No teratogenic effects (no congenital malformations)
• Survivors of hydrops have normal neurodevelopment [19,28]
• Spontaneous resolution of hydrops occurs in ~30% without intervention

Articular Complications

• Acute Arthropathy: 60% adult women, 30% adult men, less than 10% children
  • Symmetrical polyarthritis (hands, wrists, knees)
  • "Duration: 2-4 weeks (can persist months, rarely > 2 years)"
  • Self-limiting - no chronic arthritis, no erosive changes
• Chronic Arthropathy: Rare, controversial whether true association
  • Some case reports of persistent arthritis years after infection
  • Mechanism unclear (persistent viral antigen vs. autoimmune trigger)

Cardiovascular Complications

Prognosis: Most cases of myocarditis are self-limiting; rare severe cases reported with fulminant heart failure

Neurological Complications (Rare)

• Encephalitis/Meningoencephalitis: Fever, headache, seizures, altered consciousness
• Peripheral Neuropathy: Brachial neuritis, Guillain-Barré-like syndrome
• Stroke: Very rare, in setting of severe anaemia or vasculitis
• Mechanism: Direct neurotropism vs. immune-mediated

Dermatological Complications

• Papular-Purpuric Gloves and Socks Syndrome (PPGSS): See Clinical Presentation
• Henoch-Schönlein Purpura-like: Vasculitis mimicking HSP
• Persistent Pruritis: Can be debilitating in some patients

Hepatic Complications

• Transient Hepatitis: Mild transaminase elevation (common, usually asymptomatic)
• Fulminant Hepatic Failure: Very rare case reports
• Mechanism: Direct viral hepatotropism or immune-mediated

Renal Complications

• Glomerulonephritis: Rare, immune complex-mediated
• Collapsing Glomerulopathy: Case reports, especially in sickle cell patients

---

9. Prognosis and Outcomes

Healthy Children

• Prognosis: Excellent
• Duration: Rash clears in 1-3 weeks (may recur with triggers up to 2-3 months)
• Complications: Extremely rare
• Immunity: Lifelong (IgG persists)
• Recurrence: No (cannot get parvovirus B19 twice)
• Impact on Daily Life: Minimal; can return to normal activities immediately

Adults with Arthropathy

• Prognosis: Good
• Resolution:
  • 50% resolve by 2 weeks
  • 80% resolve by 2 months
  • 95% resolve by 6 months
  • Rare cases persist up to 2 years but eventually resolve
• No chronic arthritis: No erosive changes, no long-term joint damage
• Functional outcome: Complete return to baseline

Transient Aplastic Crisis

• Prognosis: Excellent with prompt treatment
• Mortality: Low (less than 1%) if recognized and transfused promptly
  • Higher mortality if delayed recognition or lack of access to transfusion
• Recovery: Bone marrow erythropoiesis resumes within 7-10 days
  • Reticulocytes reappear, Hb rises
  • Transfusion independence regained
• Long-term:
  • No recurrence (lifelong immunity after infection)
  • Patient can be counselled they will never have another aplastic crisis from B19V
• Complications: Rare (cardiac failure if severe anaemia untreated)

Chronic Pure Red Cell Aplasia (Immunocompromised)

• Prognosis: Good with IVIG treatment
• Response to IVIG: > 80% achieve remission
  • Reticulocytes return, Hb rises
  • B19V PCR becomes negative
  • Transfusion independence
• Relapse: 10-20% relapse when IVIG effect wanes
  • May require repeat or maintenance IVIG
• Prognosis without treatment: Persistent transfusion-dependent anaemia

Pregnancy and Fetal Outcomes

Maternal Outcomes

• Maternal morbidity: Minimal (B19V is not more severe in pregnancy)
• Maternal mortality: Not increased
• Long-term maternal health: No sequelae

Fetal Outcomes

Overall Fetal Loss Rate: 6-10% if maternal infection during pregnancy [19]

Stratified by Gestational Age:

If Hydrops Develops:

• Untreated: High mortality (50-70%)
• With Intrauterine Transfusion (IUT): Survival > 80% [28,38]
• Spontaneous Resolution: Occurs in ~30% of cases

Long-Term Neurodevelopmental Outcomes: [38]

• Fetuses treated with IUT: Normal neurodevelopment in vast majority
• Spontaneous hydrops resolution: Normal neurodevelopment
• Reassuring Data: No evidence of long-term sequelae in survivors
• No teratogenic effects: Unlike rubella, CMV, Zika - no structural malformations

Key Counselling Point: While the immediate risk of hydrops is serious, if the fetus survives (with or without intervention), long-term outcomes are excellent.

Prevention of Recurrence

• Immunity: Lifelong after natural infection (IgG persists)
• Cannot get B19V twice: Once infected and recovered, individual is protected
• High-risk patients: After recovery from aplastic crisis, counsel that it will not happen again from B19V
  • Other causes of aplastic crisis still possible (other infections, sequestration)
  • But B19V-induced TAC is a "one-time event"

Quality of Life

• Healthy individuals: No impact on long-term quality of life
• High-risk groups: Full recovery to baseline after acute event
• Pregnancy: No long-term maternal effects; fetal survivors have normal outcomes

---

10. Prevention

Primary Prevention

Vaccine Development

• Current Status: No licensed vaccine available
• Research:
  • Experimental vaccines (recombinant VP1/VP2 capsid proteins) have shown promise in phase I/II trials
  • "Challenges: Relatively low disease burden (most infections benign), cost-benefit considerations"
  • "Target populations would be: High-risk haematology patients, women planning pregnancy, healthcare/childcare workers"
• Timeline: Not imminently available for clinical use [39]

Transmission Reduction Measures

Individual Level:

• Hand Hygiene: Regular handwashing (especially after contact with children, school/childcare settings)
• Respiratory Hygiene: Cover coughs/sneezes, use tissues, dispose appropriately
• Avoid Sharing: Cups, utensils, towels during symptomatic phase

Limitations:

• Most transmission occurs during prodromal phase when symptoms are non-specific
• By the time diagnosis is made (rash appears), transmission has already occurred
• Makes prevention challenging in community settings

Occupational Health Measures

Pregnant Healthcare Workers and Teachers: [9,35]

• Serology Screening:
  • Offer B19V IgG testing to pregnant staff, especially during outbreaks
  • "If IgG positive (immune): Reassure, no restrictions"
  • "If IgG negative (non-immune): Counsel on risk, consider redeployment"
• Redeployment Options (during outbreaks):
  • Avoid paediatric wards, infectious diseases units
  • Avoid primary school teaching during outbreaks
  • Consider administrative duties or areas with lower exposure
• Universal Precautions: Standard infection control (hand hygiene, droplet precautions for symptomatic patients)

Limitations:

• Routine exclusion from work not recommended (sporadic community exposure cannot be prevented)
• Individual risk assessment and informed choice

Secondary Prevention (Post-Exposure)

Pregnant Women

After Identified Exposure: [35]

1. Urgent Serology: B19V IgM/IgG

   • If IgG positive: Immune, reassure
   • If negative: Susceptible, repeat in 4 weeks

2. Surveillance if Infection Confirmed:

   • Weekly ultrasound + MCA Doppler for 12 weeks
   • Early detection of hydrops allows timely intervention

3. No Post-Exposure Prophylaxis Available:

   • IVIG has been tried in some cases but efficacy unproven
   • Standard practice: Surveillance and early intervention if hydrops develops

High-Risk Haematology Patients

After Identified Exposure (e.g., household contact with slapped cheek):

1. Serology: Check B19V IgG

   • If IgG positive: Immune, no risk
   • If IgG negative: Non-immune, at risk

2. Counselling:

   • Warn about symptoms of aplastic crisis (pallor, fatigue, breathlessness)
   • Advise to seek urgent medical attention if symptoms develop

3. No Prophylaxis: IVIG not routinely given prophylactically (expensive, efficacy unproven)

4. Monitoring:

   • Some centres check FBC and reticulocytes weekly for 2-3 weeks post-exposure (controversial)
   • Allows early detection of anaemia

Immunocompromised Patients

• Serology: B19V IgG if known exposure
• Surveillance: Monitor FBC if non-immune
• IVIG: Not given prophylactically (reserved for treatment if chronic PRCA develops)

Tertiary Prevention (Preventing Complications)

Early Recognition and Treatment

Aplastic Crisis:

• Educate families of children with sickle cell disease, spherocytosis about signs/symptoms
• Action Cards: "Seek urgent help if sudden pallor, tiredness, breathlessness"
• Emergency Management Protocols: Rapid transfusion access
• Result: Early transfusion prevents cardiac failure, mortality

Hydrops Fetalis:

• Surveillance Protocol: Weekly ultrasound + MCA Doppler for at-risk pregnancies
• Fetal Medicine Expertise: Intrauterine transfusion capability
• Result: > 80% survival with timely IUT

Chronic PRCA:

• Monitor immunocompromised patients with unexplained anaemia
• B19V PCR in persistent anaemia with reticulocytopenia
• Early IVIG: Prevents prolonged transfusion dependence

Blood and Organ Donor Screening

Blood Products: [20]

• Nucleic Acid Testing (NAT): Detects B19V DNA in donated blood
• Viral Inactivation: Pathogen reduction technologies for plasma products
• Clotting Factors: Screened and treated to reduce transmission risk

Organ Transplantation:

• Donor screening in some centres (especially for immunocompromised recipients)

Result: Rare transmission via blood products/transplantation in modern era

Public Health Education

Key Messages:

1. School Exclusion Not Necessary: Once rash appears, child not infectious
2. Pregnant Women: Seek medical advice if exposed
3. High-Risk Groups: Awareness of aplastic crisis symptoms
4. Hand Hygiene: General infection prevention

---

11. Evidence and Guidelines

Key Guidelines

Exam Detail: High-Yield Guidelines for Examinations:

Landmark Studies

1. Enders et al. (2004) - Fetal Risk Quantification

Citation: Enders M, et al. "Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection." J Clin Microbiol. 2004;42:1519-1525. PMID: 15070998 [40]

Study Design: Prospective cohort of 427 pregnant women with serologically confirmed acute B19V infection

Key Findings:

• Overall fetal loss rate: 6.3%
• Highest risk: less than 20 weeks gestation (10-15% loss)
• Hydrops occurred in 2.9% of cases
• Peak time to hydrops: 2-6 weeks post-maternal infection

Impact:

• Defined risk counselling data for pregnant women
• Established surveillance window (12 weeks)
• Informed RCOG guidance

2. Fairley et al. (1995) - Intrauterine Transfusion Outcomes

Citation: Fairley CK, et al. "Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection." Lancet. 1995;346:1335-1337. PMID: 7475774 [38]

Study Design: Retrospective analysis of fetuses with B19V-induced hydrops

Key Findings:

• Spontaneous resolution of hydrops: ~30% of cases
• Survival with intrauterine transfusion: > 80%
• Neurodevelopmental outcomes: Normal in survivors

Impact:

• Established IUT as standard treatment for severe hydrops
• Reassuring long-term outcome data
• Balanced approach (watch for spontaneous resolution vs. early intervention)

3. Young & Brown (2004) - Comprehensive Review

Citation: Young NS, Brown KE. "Parvovirus B19." N Engl J Med. 2004;350:586-597. PMID: 14762186 [1]

Study Type: Landmark review article

Key Contributions:

• Detailed pathophysiology (P antigen receptor, erythroid tropism)
• Clinical spectrum across populations
• Management paradigms

Impact: Most cited reference text for B19V

4. Heegaard & Brown (2002) - Virology and Immunology

Citation: Heegaard ED, Brown KE. "Human parvovirus B19." Clin Microbiol Rev. 2002;15:485-505. PMID: 12097253 [2]

Study Type: Comprehensive review

Key Contributions:

• Molecular structure and replication
• Immune response phases (viraemic vs. immune complex)
• Diagnostic testing interpretation

Impact: Standard reference for laboratory aspects

5. Lamont et al. (2011) - UK Surveillance Study

Citation: Lamont RF, et al. "Parvovirus B19 infection in human pregnancy." BJOG. 2011;118:175-186. PMID: 21040396 [19]

Study Design: Systematic review and meta-analysis

Key Findings:

• Vertical transmission rate: 30-50% of maternal infections
• Congenital anomaly rate: No increase (not teratogenic)
• Gestational age-stratified risks

Impact:

• Clarified that B19V is NOT teratogenic (unlike TORCH infections)
• Risk stratification by trimester

6. Servant-Delmas et al. (2010) - Chronic PRCA and IVIG

Citation: Servant-Delmas A, et al. "Persistent parvovirus B19 infection in immunocompromised patients." Transfusion. 2010;50:2495-2500. PMID: 20576019 [30]

Study Design: Case series of immunocompromised patients with chronic B19V

Key Findings:

• IVIG response rate: > 80% clearance of virus and recovery from anaemia
• Relapse rate: ~15-20%
• Maintenance IVIG effective for relapses

Impact: Established IVIG as first-line treatment for chronic PRCA

7. Naides et al. (1990) - Arthropathy in Adults

Citation: Naides SJ. "Rheumatic manifestations of parvovirus B19 infection." Rheum Dis Clin North Am. 1998;24:375-401. PMID: 9606763 [13]

Study Design: Clinical series and review

Key Findings:

• 60% of adult women with B19V develop arthropathy
• Symmetrical, small joint distribution
• Seronegative (RF negative, anti-CCP negative)
• Self-limiting (weeks-months)

Impact:

• Defined B19V arthropathy as important differential for acute polyarthritis
• Reassurance regarding long-term prognosis (no chronic arthritis)

Evidence Level Summary

---

12. Examination Focus

High-Yield Exam Topics

Exam Detail: For MRCPCH:

1. Infectivity window: Not infectious once rash appears (school exclusion policy)
2. Aplastic crisis: Reticulocyte count differentiates from other crises in sickle cell disease
3. Pregnancy risks: Hydrops, no teratogenicity
4. Viral exanthem differentiation: Slapped cheek vs. measles vs. rubella vs. roseola vs. scarlet fever

For MRCOG:

1. Pregnancy management algorithm: Serology interpretation, MCA Doppler, IUT indications
2. Risk stratification by gestational age
3. Occupational health: Pregnant healthcare workers/teachers

For MRCP:

1. Adult arthropathy: Mimics RA, seronegative, self-limiting
2. Differential diagnosis: Acute polyarthritis in young woman
3. Immunocompromised: Chronic PRCA, IVIG treatment

Common Exam Questions and Model Answers

Question 1: Paediatrics - School Exclusion

Question: "A 6-year-old child presents with the characteristic 'slapped cheek' rash. The parents ask whether the child should stay off school. What is your advice?"

Model Answer: "I would reassure the parents that the child can return to school immediately if they feel well enough. The key point is that Parvovirus B19 (which causes slapped cheek syndrome) is only infectious during the prodromal phase - when the child had non-specific symptoms like fever and runny nose about a week ago. Once the characteristic facial rash appears, the virus has been cleared from the blood and the child is no longer infectious.

Public Health England guidance confirms there is no need for school exclusion once the rash is present. However, I would advise the school to inform:

• Pregnant staff members (so they can seek medical advice if concerned)
• Parents of children with sickle cell disease or other blood disorders (as they are at risk of complications)

I would also counsel the parents that the rash may fade and reappear over the next few weeks with triggers like heat, sunlight, or exercise - this is normal and does not mean the child is infectious again."

---

Question 2: Haematology - Aplastic Crisis

Question: "A 7-year-old child with sickle cell disease presents to A&E with severe pallor and lethargy. Hb is 55 g/L (baseline 80 g/L). What investigation will help differentiate aplastic crisis from other causes, and what would you expect to find?"

Model Answer: "The most useful investigation is the reticulocyte count.

In aplastic crisis (caused by Parvovirus B19):

• Reticulocytes are very low (less than 0.2%, often near-zero or absent)
• This reflects bone marrow arrest of red cell production
• The virus destroys erythroid progenitor cells
• Hb falls rapidly because sickle cells have a short lifespan (10-20 days) and no new cells are being made

In contrast, other causes of acute anaemia in sickle cell disease show high reticulocytes:

• Splenic sequestration: Reticulocytes > 5%, rapidly enlarging spleen, hypovolaemia
• Hyperhaemolytic crisis: Reticulocytes > 5%, jaundice, high bilirubin and LDH

Additional supportive findings in aplastic crisis:

• Absence of jaundice (haemolysis reduced during aplasia)
• Parvovirus B19 IgM positive or PCR positive
• Leucopenia and thrombocytopenia (bone marrow suppression)

Management:

• Urgent blood transfusion (10-15 mL/kg packed red cells)
• Supportive care, oxygen
• Isolation (to protect other at-risk patients)
• Bone marrow recovers in 7-10 days
• Patient will have lifelong immunity - aplastic crisis from B19V cannot recur"

---

Question 3: Obstetrics - Pregnancy Management

Question: "A pregnant woman at 16 weeks gestation presents to antenatal clinic. Her 5-year-old daughter has just been diagnosed with slapped cheek syndrome. How do you manage this situation?"

Model Answer: "This requires urgent assessment because 16 weeks is within the high-risk period for fetal complications from Parvovirus B19.

Step 1: Assess maternal immunity

• Take urgent B19V serology (IgM and IgG)
• Most likely outcome: IgG positive (immune) - affects 50-60% of women
  • "If immune: Reassure - no risk to fetus, no further action"

Step 2: If serology suggests infection

• IgM positive, IgG negative or positive = Acute/recent infection
  • Immediate referral to Fetal Medicine

Step 3: If non-immune (both IgM and IgG negative)

• Susceptible but not yet infected
• Repeat serology in 4 weeks (to check for seroconversion)
• May also repeat at 2 weeks given very recent exposure

Step 4: Fetal surveillance if maternal infection confirmed

• Weekly ultrasound for 12 weeks post-maternal infection
• MCA Doppler (Middle Cerebral Artery peak systolic velocity)
  • PSV > 1.5 MoM indicates fetal anaemia
• Look for signs of hydrops fetalis: skin oedema, ascites, pleural effusions, pericardial effusion

Step 5: If hydrops develops

• Cordocentesis (measure fetal Hb, confirm B19V)
• Intrauterine transfusion if severe anaemia
• Survival > 80% with IUT

Counselling:

• Overall fetal loss risk at 16 weeks: 2-5%
• Hydrops risk: 2-6%
• No teratogenic risk - B19V does not cause structural malformations (unlike rubella/CMV)
• Most hydrops occurs 2-6 weeks post-maternal infection
• 30% of hydrops cases resolve spontaneously
• Survivors have normal neurodevelopmental outcomes

Occupational advice: If she is a teacher/healthcare worker, may need redeployment if non-immune and ongoing outbreak"

---

Question 4: Rheumatology - Adult Arthropathy

Question: "A 28-year-old woman presents with sudden onset symmetrical polyarthritis affecting her hands, wrists, and knees. She reports a 'flu-like illness' 2 weeks ago. Rheumatoid factor and anti-CCP antibodies are negative. What is your differential diagnosis and how would you investigate?"

Model Answer: "The acute onset, symmetrical small joint distribution, and seronegative serology in a young woman make Parvovirus B19 arthropathy a leading differential. The flu-like illness 2 weeks ago fits the timeline (arthritis occurs during the immune complex phase, ~2 weeks post-infection).

Differential Diagnosis:

1. Parvovirus B19 arthritis (most likely)
2. Other viral arthritis: EBV, Hepatitis B, Rubella, Alphaviruses
3. Early Rheumatoid Arthritis (seronegative RA exists in 30%)
4. Reactive Arthritis (but typically asymmetrical, lower limb)
5. Early SLE (but would expect ANA positive)

Investigations:

• Parvovirus B19 IgM and IgG: IgM positive confirms recent infection
• Full autoimmune screen: ANA, anti-dsDNA, ENA (for SLE)
• Viral serology: EBV, Hepatitis B/C (if risk factors)
• Inflammatory markers: CRP, ESR (elevated in active inflammation)
• X-rays of hands/feet: No erosions in B19V (unlike RA)
• Ultrasound/MRI: May show synovitis but no bone damage

Additional History:

• Rash? (may be absent in 80% of adults with B19V)
• Contact with children? (e.g., school, childcare, own children)
• Pregnancy status? (important if B19V confirmed - though arthritis occurs post-viraemic phase, check immunity)

Management if B19V confirmed:

• Reassurance: Self-limiting, no chronic arthritis
• Symptomatic treatment: NSAIDs (ibuprofen 400 mg TDS, naproxen 500 mg BD), paracetamol
• Duration: Most resolve 2-4 weeks, can persist months but eventually resolves
• No DMARDs or steroids needed

Follow-up:

• Review in 4-6 weeks
• If symptoms persist or worsen, or if new features develop (rash, multisystem involvement), reconsider diagnosis (e.g., evolving RA, SLE)"

---

Viva Scenarios

Viva 1: Mechanism of Anaemia

Examiner: "Explain the pathophysiology of why Parvovirus B19 causes severe anaemia in patients with sickle cell disease but only mild anaemia in healthy individuals."

Model Answer: "This relates to red blood cell kinetics and the virus's tropism for erythroid progenitor cells.

Viral Mechanism:

• Parvovirus B19 binds to the P antigen (globoside) on erythroid progenitor cells in the bone marrow
• It is directly cytotoxic to these cells, causing apoptosis
• This results in arrest of erythropoiesis for approximately 7-10 days

Normal Host (RBC lifespan 120 days):

• Daily RBC turnover is only ~0.8% (1/120th of circulating RBCs)
• During the 7-10 day arrest, the large reservoir of circulating mature RBCs (120-day lifespan) compensates
• Hb drops only 5-10 g/L - usually asymptomatic
• Reticulocytes fall transiently but Hb remains stable

Sickle Cell Disease Host (RBC lifespan 10-20 days):

• Chronic haemolysis means RBC lifespan is drastically shortened
• Daily RBC turnover is 5-10% (5-10x higher than normal)
• Bone marrow operates at maximal capacity just to maintain steady-state Hb (70-90 g/L)
• Baseline reticulocyte count is very high (10-20%) reflecting this compensatory effort

When B19V arrests erythropoiesis:

• No new RBCs are produced for 7-10 days
• But ongoing rapid destruction continues (short RBC lifespan)
• Hb falls precipitously (can drop 30-50 g/L in days)
• Reticulocytes fall to near-zero
• Transient Aplastic Crisis ensues - life-threatening anaemia

Similar Mechanism in Fetus:

• Fetal RBCs have shorter lifespan (45-70 days)
• Rapidly expanding blood volume (growth)
• Arrest of erythropoiesis → severe fetal anaemia → high-output cardiac failure → hydrops fetalis

Clinical Implication: The reticulocyte count is the key diagnostic test - it differentiates aplastic crisis (low reticulocytes) from other causes of acute anaemia in haemolytic conditions (high reticulocytes, such as sequestration or hyperhaemolysis)."

---

Viva 2: MCA Doppler

Examiner: "A pregnant woman has confirmed acute Parvovirus B19 infection at 18 weeks. You arrange weekly MCA Doppler scans. Explain the rationale and interpretation."

Model Answer: "MCA Doppler (Middle Cerebral Artery Doppler ultrasound) is a non-invasive method to detect fetal anaemia.

Rationale:

• Parvovirus B19 infection can cause fetal anaemia and hydrops fetalis
• Peak risk period is 2-6 weeks post-maternal infection (but can occur up to 12 weeks later)
• We need to monitor for developing fetal anaemia to intervene before severe hydrops develops
• MCA Doppler allows detection of anaemia without invasive procedures (cordocentesis)

Mechanism:

• Fetal anaemia reduces blood viscosity (fewer red cells = thinner blood)
• To maintain oxygen delivery, cardiac output increases
• Blood flow velocity through vessels increases
• The Middle Cerebral Artery is the most sensitive vessel for detecting this change
• We measure the Peak Systolic Velocity (PSV)

Interpretation:

• PSV is compared to gestational age-specific normal ranges (Multiples of Median, MoM)
• PSV less than 1.5 MoM: Normal, reassuring
• PSV ≥1.5 MoM: Moderate to severe fetal anaemia likely
• PSV ≥1.55 MoM: Strong indication for intrauterine transfusion

Surveillance Protocol:

• Weekly MCA Doppler for 12 weeks post-maternal infection
• Also perform detailed ultrasound to look for signs of hydrops:
  • Skin oedema (> 5mm subcutaneous fluid)
  • Ascites
  • Pleural effusions
  • Pericardial effusion
  • Placentomegaly

If MCA Doppler Abnormal:

• Referral to Fetal Medicine for consideration of:
  • "Cordocentesis: Direct fetal blood sampling to measure Hb"
  • "Intrauterine Transfusion (IUT): Ultrasound-guided transfusion into umbilical vein"
  • May require repeat transfusions until fetal bone marrow recovers (6-8 weeks)
• Outcome: > 80% survival with IUT

Advantages of MCA Doppler:

• Non-invasive (cf. cordocentesis which has 1-2% fetal loss risk)
• Can be repeated weekly without risk
• Allows early detection before overt hydrops develops

Limitations:

• Operator-dependent
• ~10% false positive rate (PSV elevated but fetus not anaemic)
• Does not replace ultrasound assessment for hydrops features"

---

Viva 3: P Antigen

Examiner: "What is the P antigen and what is its significance in Parvovirus B19 infection?"

Model Answer: "The P antigen (globoside, Gb4Cer) is a glycosphingolipid present on cell membranes. It is the primary cellular receptor for Human Parvovirus B19.

Molecular Function:

• P antigen binds to the VP1 and VP2 capsid proteins of B19V
• This receptor-ligand interaction mediates viral entry into host cells
• After binding, viral entry is facilitated by co-receptors (α5β1 integrin, Ku80)

Tissue Distribution:

• Highly expressed on:
  • Erythroid progenitor cells (CFU-E, proerythroblasts) in bone marrow
  • Megakaryocytes
  • Endothelial cells
  • Fetal cardiomyocytes
• Low or absent on:
  • Mature erythrocytes
  • Most other somatic cells

Clinical Significance - Explains Tropism:

1. Erythroid tropism: High P antigen on erythroid progenitors → bone marrow infection → erythropoiesis arrest
2. Fetal myocarditis: P antigen on fetal cardiomyocytes → myocardial infection → cardiac dysfunction (contributes to hydrops)
3. Vascular effects: Endothelial P antigen → vasculitis (e.g., Gloves and Socks Syndrome)

P-Null Individuals (Rare):

• Approximately 1 in 200,000 individuals lack P antigen (p phenotype)
• Naturally immune to B19V infection (virus cannot enter cells)
• Also lack the P blood group antigen
• Demonstrates the critical importance of P antigen for infection

Diagnostic Relevance:

• Understanding P antigen distribution explains why:
  • B19V targets bone marrow (high P antigen on erythroid cells)
  • Anaemia is the major complication
  • Fetal myocardium is affected (hydrops mechanism)
  • Most tissues are spared (low P antigen expression)

Research Implications:

• P antigen is a potential therapeutic target (blocking P antigen could prevent infection)
• Used in vaccine development strategies"

---

13. Patient and Layperson Explanation

What is Slapped Cheek Syndrome?

Slapped Cheek Syndrome, also called Fifth Disease or Erythema Infectiosum, is a very common childhood viral infection. It is caused by a virus called Parvovirus B19. Most children will get this infection at some point during childhood.

Why is it called "Slapped Cheek"?

The illness gets its name from the characteristic bright red rash that appears on both cheeks, making it look like the child has been slapped on the face. This is followed by a pink, lacy rash on the body, arms, and legs.

How does it spread?

The virus spreads through coughing and sneezing (respiratory droplets), similar to a cold. It is very contagious, and children can easily spread it to others - but only before the rash appears.

Here's the important part: by the time your child has the red cheeks, they are no longer contagious. They were infectious about a week earlier when they just had cold-like symptoms (runny nose, mild fever). This is why it's hard to prevent the spread - no one knows the child has slapped cheek until it's too late!

What are the symptoms?

Stage 1: Early symptoms (1-2 weeks before rash)

• Mild fever (usually low-grade)
• Runny nose
• Headache
• Feeling tired
• These symptoms are very mild and often go unnoticed - just like a common cold

Stage 2: Red cheeks (1-2 weeks later)

• Sudden appearance of bright red cheeks (both sides)
• The area around the mouth stays pale
• Cheeks may feel warm but not painful

Stage 3: Body rash (1-4 days after red cheeks)

• Pink, lacy rash on arms, legs, and body
• Looks like a net or lace pattern
• May be slightly itchy
• Lasts 1-3 weeks

Stage 4: Rash comes and goes

• The rash may fade and then come back for several weeks
• Triggers include: hot baths, exercise, sunlight, stress, cold
• This is completely normal and does NOT mean your child is infectious again

Is it dangerous?

For most children: NO - it is a mild illness that goes away on its own.

However, there are some groups who need to be careful:

1. Pregnant Women:

   • If a pregnant woman who has never had slapped cheek before catches it, there is a small risk to the baby
   • The virus can cause anaemia (low blood count) in the baby
   • Pregnant women should see their doctor or midwife if they have been in contact with someone who has slapped cheek
   • Most pregnant women are already immune (they had it as a child), so usually there is no problem

2. Children with Blood Disorders (like sickle cell disease, thalassaemia):

   • The virus can cause a sudden drop in their blood count, making them very pale and tired
   • This is called an "aplastic crisis" and needs urgent hospital treatment
   • If your child has a blood disorder and becomes very pale and tired, seek medical help immediately

3. People with Weak Immune Systems:

   • Children or adults on chemotherapy, with HIV, or taking medicines that suppress the immune system
   • The infection can last longer and cause ongoing anaemia

Can my child go to school?

YES! Once the rash appears, your child is no longer contagious and can return to school if they feel well enough.

There is no need to keep them off school or away from other children.

Treatment

For healthy children:

• No specific treatment is needed
• The illness goes away on its own
• You can give paracetamol or ibuprofen for fever or discomfort
• Encourage your child to drink plenty of fluids
• Rest if tired

For high-risk groups (pregnancy, blood disorders):

• Close monitoring by a doctor
• Special treatments may be needed (e.g., blood transfusions, immunoglobulin injections)

When should I see a doctor?

Most children do not need to see a doctor for slapped cheek syndrome. However, seek medical advice if:

• Your child becomes very pale, extremely tired, or breathless
• You are pregnant and have been in contact with someone who has slapped cheek (especially if you don't know if you've had it before)
• Your child has a blood disorder (sickle cell, thalassaemia, etc.) and develops new symptoms
• Your child has a weakened immune system
• Your child develops severe headache, neck stiffness, or drowsiness
• You are worried for any other reason

Can you get it more than once?

No - once you have had slapped cheek syndrome, you are immune for life. You cannot get it again.

Is there a vaccine?

No, there is currently no vaccine available for Parvovirus B19.

Summary for Parents

• Slapped cheek is a common, usually mild childhood illness
• It causes bright red cheeks followed by a lacy body rash
• Not contagious once the rash appears - child can return to school
• Rash may come and go for weeks with heat/sun - this is normal
• No treatment needed for healthy children - it goes away on its own
• Pregnant women and children with blood disorders should seek medical advice if exposed
• Once infected, your child is immune for life

Helpful Analogy

Think of slapped cheek like a party invitation that arrives late: by the time you get the invitation (the rash), the party (the infectious period) is already over! Your child was spreading the virus when they just had a runny nose last week - before anyone knew it was slapped cheek.

---

14. References

Primary Sources

1. Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-597. doi:10.1056/NEJMra030840. PMID: 14762186.

2. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15(3):485-505. doi:10.1128/CMR.15.3.485-505.2002. PMID: 12097253.

3. Servant A, Laperche S, Lallemand F, et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002;76(18):9124-9134. doi:10.1128/JVI.76.18.9124-9134.2002. PMID: 12186896.

4. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993;262(5130):114-117. doi:10.1126/science.8211117. PMID: 8211117.

5. Cooling LL, Koerner TA, Naides SJ. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis. 1995;172(5):1198-1205. doi:10.1093/infdis/172.5.1198. PMID: 7594653.

6. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152(2):257-265. doi:10.1093/infdis/152.2.257. PMID: 2991401.

7. Anderson LJ, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986;24(4):522-526. doi:10.1128/jcm.24.4.522-526.1986. PMID: 3021800.

8. Plummer FA, Hammond GW, Forward K, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med. 1985;313(2):74-79. doi:10.1056/NEJM198507113130202. PMID: 2582257.

9. Public Health England. Guidance on infection control in schools and other childcare settings. 2017. Updated 2019. Available: https://www.gov.uk/government/publications/health-protection-in-schools-and-other-childcare-facilities

10. Serjeant GR, Topley JM, Mason K, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981;2(8247):595-597. doi:10.1016/s0140-6736(81)92739-2. PMID: 6116083.

11. Harms M, Feldmann R, Saurat JH. Papular-purpuric "gloves and socks" syndrome. J Am Acad Dermatol. 1990;23(5 Pt 1):850-854. doi:10.1016/0190-9622(90)70305-5. PMID: 2172356.

12. White DG, Woolf AD, Mortimer PP, et al. Human parvovirus arthropathy. Lancet. 1985;1(8426):419-421. doi:10.1016/s0140-6736(85)91206-x. PMID: 2857806.

13. Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am. 1998;24(2):375-401. doi:10.1016/s0889-857x(05)70011-7. PMID: 9606763.

14. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330(17):1192-1196. doi:10.1056/NEJM199404283301704. PMID: 8139628.

15. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 1988;25(2):151-153. doi:10.1099/00222615-25-2-151. PMID: 3339631.

16. Kelly HA, Siebert D, Hammond R, et al. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000;124(3):449-457. doi:10.1017/s0950268899003817. PMID: 10982070.

17. Bell LM, Naides SJ, Stoffman P, et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321(8):485-491. doi:10.1056/NEJM198908243210801. PMID: 2548104.

18. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105(2):174-178. doi:10.1111/j.1471-0528.1998.tb10047.x. PMID: 9501781.

19. Lamont RF, Sobel JD, Vaisbuch E, et al. Parvovirus B19 infection in human pregnancy. BJOG. 2011;118(2):175-186. doi:10.1111/j.1471-0528.2010.02749.x. PMID: 21040396.

20. Kleinman SH, Glynn SA, Lee TH, et al. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. 2009;114(17):3677-3683. doi:10.1182/blood-2009-06-225342. PMID: 19675305.

21. Servant-Delmas A, Lefrère JJ, Morinet F, Pillet S. Advances in human B19 erythrovirus biology. J Virol. 2010;84(19):9658-9665. doi:10.1128/JVI.00684-10. PMID: 20660195.

22. Ozawa K, Kurtzman G, Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science. 1986;233(4766):883-886. doi:10.1126/science.3738514. PMID: 3738514.

23. Morey AL, Ferguson DJ, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis. J Pathol. 1993;169(2):213-220. doi:10.1002/path.1711690209. PMID: 8445488.

24. Smith-Whitley K, Zhao H, Hodinka RL, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood. 2004;103(2):422-427. doi:10.1182/blood-2003-01-0069. PMID: 12969985.

25. Rodis JF, Quinn DL, Gary GW Jr, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol. 1990;163(4 Pt 1):1168-1171. doi:10.1016/0002-9378(90)90683-4. PMID: 2171321.

26. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet. 1988;2(8621):1159-1162. doi:10.1016/s0140-6736(88)90233-4. PMID: 2903412.

27. Cassinotti P, Siegl G. Quantitative evidence for persistence of human parvovirus B19 DNA in an immunocompetent individual. Eur J Clin Microbiol Infect Dis. 2000;19(11):886-887. doi:10.1007/s100960000382. PMID: 11152316.

28. Cosmi E, Mari G, Delle Chiaie L, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia resulting from parvovirus infection. Am J Obstet Gynecol. 2002;187(5):1290-1293. doi:10.1067/mob.2002.127376. PMID: 12439522.

29. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926-933. doi:10.7326/0003-4819-113-12-926. PMID: 2173461.

30. Servant-Delmas A, Lefrère JJ, Morinet F, Pillet S. Advances in human B19 erythrovirus biology. J Virol. 2010;84(19):9658-9665. doi:10.1128/JVI.00684-10. PMID: 20660195.

31. Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet. 1983;1(8338):1378. doi:10.1016/s0140-6736(83)92152-9. PMID: 6134164.

32. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149(5):1153-1156. PMID: 2541664.

33. Saarinen UM, Chorba TL, Tattersall P, et al. Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood. 1986;67(5):1411-1417. PMID: 3008891.

34. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med. 2000;342(1):9-14. doi:10.1056/NEJM200001063420102. PMID: 10620643.

35. Royal College of Obstetricians and Gynaecologists. Parvovirus B19 Infection in Pregnancy. Green-top Guideline No. 4. 2014 (updated). Available: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/parvovirus-b19-infection-in-pregnancy-green-top-guideline-no-4/

36. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517. PMID: 25203083.

37. Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med. 1987;317(5):287-294. doi:10.1056/NEJM198707303170508. PMID: 3037380.

38. Fairley CK, Smoleniec JS, Caul OE, Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995;346(8986):1335-1337. doi:10.1016/s0140-6736(95)92345-2. PMID: 7475774.

39. Bansal GP, Hatfield JA, Dunn FE, et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis. 1993;167(5):1034-1044. doi:10.1093/infdis/167.5.1034. PMID: 8387557.

40. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24(7):513-518. doi:10.1002/pd.940. PMID: 15300741.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to current local/national guidelines for management protocols.